Bio-Path (BPTH) appoints Vikram Grover CEO & CFO; board shifts

Bio-Path Holdings (BPTH) announced leadership changes.

Rhea-AI Filing Summary

Bio-Path Holdings (BPTH) announced leadership changes. On October 22, 2025, the Board appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and a member of the Board. The Board also accepted the resignation of Douglas Morris as Interim CEO and Interim CFO; he remains on the Board. In addition, Paul Aubert resigned as a Director.

This consolidates executive leadership under one individual while maintaining board continuity through Mr. Morris’s continued service. The filing does not include financial results or strategic updates, focusing solely on governance and leadership transitions.

Insights

Corporate governance analyst

Leadership consolidated; governance continuity maintained.

Bio-Path appointed Vikram Grover as President, CEO, CFO, and Director on October 22, 2025. Consolidating CEO and CFO roles centralizes decision-making and reporting structures within a single executive.

Douglas Morris stepped down as Interim CEO and Interim CFO but remains on the Board, providing continuity. Paul Aubert resigned from the Board, reducing its composition by one seat per this disclosure.

Actual operational impact depends on subsequent strategic actions and any future disclosures on responsibilities or board reconstitution. Subsequent filings may provide additional detail.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 11:40 AM EDT Learn about SEC filing dates

false 0001133818 0001133818 2025-10-22 2025-10-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 22, 2025

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36333		87-0652870
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas		77401
(Address of principal executive offices)		(Zip Code)

(832) 742-1357

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		BPTH		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On October 22, 2025, the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) elected and appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and member of the Board.

On October 22, 2025, the Board of the Company accepted the resignation of Douglas Morris as Interim Chief Executive Officer and Interim Chief Financial Officer. Mr. Morris continues to be a member of the Board.

On October 22, 2025, the Board of the Company accepted the resignation of Paul Aubert as Director.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIO-PATH HOLDINGS, INC.
Dated: October 29, 2025	By:	/s/ Vikram Grover
		Vikram Grover
		Chief Executive Officer, Chief Financial Officer and Director

3